-
Article
Open AccessReal-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer
Afatinib, a second-generation epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitor (TKI) for mutant non-small cell lung cancer (NSCLC), was approved in Japan in 2014. This study evaluated clinical...
-
Article
Open AccessA phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations
This phase I trial was conducted to determine the maximum tolerated dose (MTD) and recommended dose of afatinib for phase II trial in elderly patients with advanced non-small cell lung cancer (NSCLC) harboring...
-
Article
Polyinosinic-Polycytidylic Acid Induces the Expression of GRO-α in BEAS-2B Cells
Growth-related oncogene protein-α (GRO-α)/CXCLl is a chemokine that activates neutrophils and plays an important role in inflammatory reactions. Polyinosinic-polycytidylic acid (poly IC) is a synthetic double-...
-
Article
Effect of Double-Stranded RNA on the Expression of Epithelial Neutrophil Activating Peptide-78/CXCL-5 in Human Endothelial Cells
Epithelial neutophil activating peptide-78 (ENA-78)/CXCL-5 is a member of CXC chemokines. ENA-78 was originally described as a factor produced by epithelial cells only. But other types of cells including vascu...